221. The Utilization of Capsid-Optimized Adeno-Associated Virus (AAV) Vectors for Cancer Immunotherapy
Molecular Therapy - United States
doi 10.1016/s1525-0016(16)33826-6
Full Text
Open PDFAbstract
Available in full text
Date
May 1, 2015
Authors
Publisher
Elsevier BV